COVID-19 Drug Therapy Info
CPhA’s clinical editors have developed and maintained a series of drug therapy information documents to support pharmacists dealing with drug shortages, special considerations and evolving evidence throughout the pandemic.
- COVID-19 in Patients taking disease-modifying therapy for the management of multiple sclerosis: General considerations for management of patients with Multiple Sclerosis during COVID-19. (Updated February 25, 2021)
- Treatment of COVID-19 with colchicine: It is not known whether there is enough benefit from using colchicine in treating COVID-19 to outweigh the risks. Until more data are available, colchicine should be restricted to use in clinical trials enrolling patients diagnosed with COVID-19. (February 2, 2021)
- Treatment of COVID-19 with remdesivir: The antiviral drug remdesivir has recently been approved for treatment of COVID-19. CPhA has reviewed the literature available to date and has developed this document outlining current evidence. This document will be updated as new evidence becomes available. (Updated November 20, 2020)
- Open Access Content: COVID-19 Chapter: CPhA’s newest chapter, COVID-19, provides information for primary care practitioners on management of common symptoms such as fever, cough and headache as well as a summary of experimental treatments being used in acute-care settings. This content will be updated regularly as new evidence becomes available. (Updated June 25, 2020)
- DMARDs or other anti-rheumatic medications: To date, there is no data on COVID-19 in patients with rheumatic disease taking DMARDs. Patients should not stop taking DMARDs without the consultation of their rheumatologist. (Updated May 14, 2020)
- Disruption of immunization schedules during the pandemic: Is a delay a problem? During the COVID-19 pandemic, many pharmacists and other providers have stopped providing routine immunization to support reallocation of health care provider time and social distancing. (March 26, 2020)
- Canadian Cardiovascular Society and the Canadian Heart Failure Society guidance on cardiovascular medications: ACEi/ARB/ARNi, low-dose ASA and NSAIDs (March 20, 2020)
Archived Material: As information and evidence has evolved throughout the pandemic, we have archived a number of our drug therapy information resources and statements.